An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets

Bibliography

• Hyman S, Chisholm D, Kessler R, et al. Mental disorders. Disease control priorities in developing Countries, 2nd edition, World Bank; Washington, DC: 2006. Chapter 31. Available from: http://www.ncbi.nlm.nih.gov/books/NBK11728/
   Google Scholar
• Kessler RC, Angermeyer M, Anthony JC, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry 2007;6:168-76
   PubMed Web of Science ®Google Scholar
• Emanuel AM, Moore TR, Ghazvini P. Considerations for the Use of Alternative Therapies in the Treatment of Depression. J Pharm Pract 2001;14:551-9
   Google Scholar
• Murray C, Lopez A. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Volume 1 The global burden of disease and injury series; Cambridge MA: 1996
   Google Scholar
• Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ 2006;9:87-98
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75
   PubMed Web of Science ®Google Scholar
• Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003;183:514-19
   PubMed Web of Science ®Google Scholar
• Schappert SM, Nelson C. National Ambulatory Medical Care Survey: 1995-96 Summary. National Center for Health Statistics Vital Health Stat 1999;13:142
   Google Scholar
• Regier DA, Myers JK, Kramer M, et al. The NIMH Epidemiologic Catchment Area program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984;41:934-41
   PubMed Web of Science ®Google Scholar
• Blyth FM, March LM, Brnabic AJ, et al. Chronic pain in Australia: a prevalence study. Pain 2001;89:127-34
   PubMed Web of Science ®Google Scholar
• Currie SR, Wang JL. Chronic back pain and major depression in the general Canadian population. Pain 2004;107:54-60
   PubMed Web of Science ®Google Scholar
• Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA 1998;280:147-51
   PubMed Web of Science ®Google Scholar
• Phillips CJ. Economic burden of chronic pain. Expert Rev Pharmacoecon Outcomes Res 2006;6:591-601
   PubMedGoogle Scholar
• Ospina M, Harstall C. Prevalence of chronic pain: an overview: Alberta Heritage Foundation for Medical Research. Edmonton, Alberta, Canada; 2002
   Google Scholar
• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333
   PubMed Web of Science ®Google Scholar
• Praemer A, Furner S, Rice DP. Musculoskeletal conditions in the United States; American Academy of Orthopaedic Surgeons. Surgeons AAoO; Park Ridge, IL; 1992
   Google Scholar
• Association AP, DSM-IV. APATFo. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. American Psychiatric Publishing, Inc; Arlington, VA; 2000
   Google Scholar
• First MB, Spitzer RL, Williams JB. Structured clinical interview for DSM-IV axis I disorders SCID-I: clinician version, administration booklet. American Psychiatric Pub; Washington, DC; 1997
   Google Scholar
• Schatzberg AF, Arnow B, Burt V, et al. Depression and physical symptoms: the mind–body connection. J Clin Psychiatry 2004;65:867-76
   Google Scholar
• Lepine JP, Briley M. The epidemiology of pain in depression. Hum Psychopharmacol 2004;19:S3-7
   PubMed Web of Science ®Google Scholar
• Arnow BA, Hunkeler EM, Blasey CM, et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom Med 2006;68:262-8
   PubMed Web of Science ®Google Scholar
• Henningsen P, Lowe B. Depression, pain, and somatoform disorders. Curr Opin Psychiatry 2006;19:19-24
   PubMed Web of Science ®Google Scholar
• Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433-45
   PubMed Web of Science ®Google Scholar
• Gureje O, Von Korff M, Kola L, et al. The relation between multiple pains and mental disorders: results from the World Mental Health Surveys. Pain 2008;135:82-91
   PubMed Web of Science ®Google Scholar
• Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60:39-47
   PubMed Web of Science ®Google Scholar
• Katon W, Sullivan M, Walker E. Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. Ann Intern Med 2001;134:917-25
   PubMed Web of Science ®Google Scholar
• Patten SB. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J Affect Disord 2001;63:35-41
   PubMed Web of Science ®Google Scholar
• Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res 2003;12:34-43
   PubMed Web of Science ®Google Scholar
• Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med 2004;19:813-18
   PubMed Web of Science ®Google Scholar
• Jackson KC II, St Onge EL. Antidepressant pharmacotherapy: considerations for the pain clinician. Pain Pract 2003;3:135-43
   PubMedGoogle Scholar
• Ang DC, Kroenke K, McHorney CA. Impact of pain severity and location on health-related quality of life. Rheumatol Int 2006;26:567-72
   PubMed Web of Science ®Google Scholar
• Bair MJ, Kroenke K, Sutherland JM, et al. Effects of depression and pain severity on satisfaction in medical outpatients: analysis of the Medical Outcomes Study. J Rehabil Res Dev 2007;44:143-52
   PubMed Web of Science ®Google Scholar
• Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17-22
   PubMed Web of Science ®Google Scholar
• Karp JF, Scott J, Houck P, et al. Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry 2005;66:591-7
   PubMed Web of Science ®Google Scholar
• Mossey JM, Gallagher RM. The longitudinal occurrence and impact of comorbid chronic pain and chronic depression over two years in continuing care retirement community residents. Pain Med 2004;5:335-48
   PubMed Web of Science ®Google Scholar
• Ohayon MM. Specific characteristics of the pain/depression association in the general population. J Clin Psychiatry 2004;65:5-9
   PubMed Web of Science ®Google Scholar
• Williams LS, Jones WJ, Shen J, et al. Outcomes of newly referred neurology outpatients with depression and pain. Neurology 2004;63:674-7
   PubMed Web of Science ®Google Scholar
• Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329-35
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96
   PubMed Web of Science ®Google Scholar
• Zung WWK, Richards CB, Short MJ. Self-rating depression scale in an outpatient clinic: further validation of the SDS. Arch Gen Psychiatry 1965;13:508
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71
   PubMed Web of Science ®Google Scholar
• Morley S, Williams AC, Black S. A confirmatory factor analysis of the Beck Depression Inventory in chronic pain. Pain 2002;99:289-98
   PubMed Web of Science ®Google Scholar
• Estlander AM, Takala EP, Verkasalo M. Assessment of depression in chronic musculoskeletal pain patients. Clin J Pain 1995;11:194-200
   PubMedGoogle Scholar
• von Ammon Cavanaugh S. Depression in the medically ill. Critical issues in diagnostic assessment. Psychosomatics 1995;36:48-59
   Google Scholar
• Lindsay PG, Wyckoff M. The depression-pain syndrome and its response to antidepressants. Psychosomatics 1981;22:571-3; 76-7
   PubMed Web of Science ®Google Scholar
• Goldenberg DL. Pain/Depression dyad: a key to a better understanding and treatment of functional somatic syndromes. Am J Med 2010;123:675-82
   PubMed Web of Science ®Google Scholar
• Gallagher RM, Verma S. Managing pain and comorbid depression: a public health challenge. Semin Clin Neuropsychiatry 1999;4:203-20
   PubMedGoogle Scholar
• Blier P, Abbott FV. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J Psychiatry Neurosci 2001;26:37-43
   PubMed Web of Science ®Google Scholar
• Dersh J, Polatin PB, Gatchel RJ. Chronic pain and psychopathology: research findings and theoretical considerations. Psychosom Med 2002;64:773-86
   PubMed Web of Science ®Google Scholar
• Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6
   PubMed Web of Science ®Google Scholar
• Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:435-51
   PubMed Web of Science ®Google Scholar
• Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992;257:1276-9
   PubMed Web of Science ®Google Scholar
• Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640-5
   PubMed Web of Science ®Google Scholar
• Bagis S, Tamer L, Sahin G, et al. Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol Int 2005;25:188-90
   PubMed Web of Science ®Google Scholar
• Maes M, Mihaylova I, Kubera M, et al. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 2010;125:287-94
   PubMed Web of Science ®Google Scholar
• Wallace DJ. Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 2006;12:17-22
   PubMed Web of Science ®Google Scholar
• Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-57
   PubMed Web of Science ®Google Scholar
• Bravo L, Alba-Delgado C, Torres-Sanchez S, et al. Social stress exacerbates the aversion to painful experiences in rats exposed to chronic pain: the role of the locus coeruleus. Pain 2013;154:2014-23
   Google Scholar
• Burke NN, Geoghegan E, Kerr DM, et al. Altered neuropathic pain behaviour in a rat model of depression is associated with changes in inflammatory gene expression in the amygdala. Genes Brain Behav 2013; Epub ahead of print
   Google Scholar
• Li B, Yang CJ, Yue N, et al. Clomipramine reverses hypoalgesia/hypoesthesia and improved depressive-like behaviors induced by inescapable shock in rats. Neurosci Lett 2013;541:227-32
   Google Scholar
• Rosenberg MB, Carroll FI, Negus SS. Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats. J Pain 2013;14:246-59
   Google Scholar
• Stratinaki M, Varidaki A, Mitsi V, et al. Regulator of G protein signaling 4 [corrected] is a crucial modulator of antidepressant drug action in depression and neuropathic pain models. Proc Natl Acad Sci USA 2013;110:8254-9
   Google Scholar
• Xu Y, Zhang L, Shao T, et al. Ferulic acid increases pain threshold and ameliorates depression-like behaviors in reserpine-treated mice: behavioral and neurobiological analyses. Metab Brain Dis 2013; Epub ahead of print
   Google Scholar
• Coluzzi F, Mattia C. Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Des 2005;11:2945-60
   PubMed Web of Science ®Google Scholar
• Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012;52:6-17
   PubMed Web of Science ®Google Scholar
• Hauser W, Wolfe F, Tolle T, et al. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012;26:297-307
   PubMed Web of Science ®Google Scholar
• Masuda R, Itoh M, Suzuki T. [Duloxetine for chronic pain management: pharmacology and clinical use]. Masui 2013;62:814-21
   Google Scholar
• Price DD. Central neural mechanisms that interrelate sensory and affective dimensions of pain. Mol Interv 2002;2:392-403; 339
   Google Scholar
• Burke NN, Hayes E, Calpin P, et al. Enhanced nociceptive responding in two rat models of depression is associated with alterations in monoamine levels in discrete brain regions. Neuroscience 2010;171:1300-13
   Google Scholar
• Fukuhara K, Ishikawa K, Yasuda S, et al. Intracerebroventricular 4-methylcatechol (4-MC) ameliorates chronic pain associated with depression-like behavior via induction of brain-derived neurotrophic factor (BDNF). Cell Mol Neurobiol 2012;32:971-7
   PubMed Web of Science ®Google Scholar
• Wang J, Goffer Y, Xu D, et al. A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats. Anesthesiology 2011;115:812-21
   PubMed Web of Science ®Google Scholar
• Bardin L, Malfetes N, Newman-Tancredi A, Depoortere R. Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: Relevance to human stress-associated painful pathologies. Behav Brain Res 2009;205:360-6
   PubMed Web of Science ®Google Scholar
• Shi M, Wang JY, Luo F. Depression shows divergent effects on evoked and spontaneous pain behaviors in rats. J Pain 2010;11:219-29
   Google Scholar
• Wang S, Tian Y, Song L, et al. Exacerbated mechanical hyperalgesia in rats with genetically predisposed depressive behavior: role of melatonin and NMDA receptors. Pain 2012;153:2448-57
   Google Scholar
• Su YL, Wang N, Gao G, et al. The effect of depression on the thermal nociceptive thresholds in rats with spontaneous pain. Neurosci Bull 2010;26:429-36
   Google Scholar
• Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967;113:1237-64
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Sheline YI. Abnormalities of serotonin metabolism and nonpsychotic psychiatric disorders. Ann Clin Psychiatry 1993;5:275-81
   Google Scholar
• John Mann J, Malone KM. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Biol Psychiatry 1997;41:162-71
   Google Scholar
• Roggenbach J, Müller-Oerlinghausen B, Franke L. Suicidality, impulsivity and aggression—is there a link to 5HIAA concentration in the cerebrospinal fluid? Psychiatry Res 2002;113:193-206
   PubMed Web of Science ®Google Scholar
• Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994;40:288-95
   PubMed Web of Science ®Google Scholar
• Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-18
   PubMed Web of Science ®Google Scholar
• Moldofsky H. Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system serotonin, and pain. Adv Neurol 1982;33:51-7
   PubMedGoogle Scholar
• Maes M, Verkerk R, Delmeire L, et al. Serotonergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgia. Psychiatry Res 2000;97:11-20
   PubMed Web of Science ®Google Scholar
• Bazzichi L, Giannaccini G, Betti L, et al. Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis Res Ther 2006;8:R99
   PubMed Web of Science ®Google Scholar
• Legangneux E, Mora JJ, Spreux-Varoquaux O, et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [H-3]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology 2001;40:290-6
   PubMed Web of Science ®Google Scholar
• Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. 1965. J Neuropsychiatry Clin Neurosci 1995;7:524-33
   PubMed Web of Science ®Google Scholar
• Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000;61:7-11
   PubMed Web of Science ®Google Scholar
• Potter WZ, Manji HK. Catecholamines in depression: an update. Clin Chem 1994;40:279-87
   PubMed Web of Science ®Google Scholar
• Basbaum AI, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984;7:309-38
   PubMed Web of Science ®Google Scholar
• Westlund K. Anatomy of noradrenergic pathways modulating pain. In: Besson JM, Guilbaud G, editors. Towards the use of noradrenergic agonists for the treatment of pain. Excerpta Medica; Amsterdam ; New York: 1992. p. 91-118
   Google Scholar
• Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474
   PubMed Web of Science ®Google Scholar
• Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 2003;26:668-77
   PubMed Web of Science ®Google Scholar
• Canavero S, Bonicalzi V, Paolotti R. Reboxetine for central pain: a single-blind prospective study. Clin Neuropharmacol 2002;25:238-9
   Google Scholar
• Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007;64:327-37
   PubMed Web of Science ®Google Scholar
• Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59:1151-9
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:781-823
   PubMed Web of Science ®Google Scholar
• Skolnick P, Krieter P, Tizzano J, et al. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev 2006;12:123-34
   PubMedGoogle Scholar
• Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-6
   PubMed Web of Science ®Google Scholar
• Gupta S, Vincent JL, Frank B. Pramipexole: augmentation in the treatment of depressive symptoms. CNS Spectr 2006;11:172-5
   PubMed Web of Science ®Google Scholar
• Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65
   PubMed Web of Science ®Google Scholar
• Lin MT, Wu JJ, Chandra A, Tsay BL. Activation of striatal dopamine receptors induces pain inhibition in rats. J Neural Transm 1981;51:213-22
   PubMedGoogle Scholar
• Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain 1995;60:3-38
   PubMed Web of Science ®Google Scholar
• Skagerberg G, Bjorklund A, Lindvall O, Schmidt RH. Origin and termination of the diencephalo-spinal dopamine system in the rat. Brain Res Bull 1982;9:237-44
   PubMed Web of Science ®Google Scholar
• Tamae A, Nakatsuka T, Koga K, et al. Direct inhibition of substantia gelatinosa neurones in the rat spinal cord by activation of dopamine D2-like receptors. J Physiol 2005;568:243-53
   PubMed Web of Science ®Google Scholar
• Magnusson JE, Fisher K. The involvement of dopamine in nociception: the role of D(1) and D(2) receptors in the dorsolateral striatum. Brain Res 2000;855(2):260-6
   PubMed Web of Science ®Google Scholar
• US VE, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol 1931;72:74-87
   Google Scholar
• Li YQ, Wang ZM, Zheng HX, Shi JW. Central origins of substance P-like immunoreactive fibers and terminals in the spinal trigeminal caudal subnucleus in the rat. Brain Res 1996;719:219-24
   PubMed Web of Science ®Google Scholar
• Cooper PE, Fernstrom MH, Rorstad OP, et al. The regional distribution of somatostatin, substance P and neurotensin in human brain. Brain Res 1981;218:219-32
   PubMedGoogle Scholar
• Feuerstein TJ, Gleichauf O, Landwehrmeyer GB. Modulation of cortical acetylcholine release by serotonin: the role of substance P interneurons. Naunyn Schmiedebergs Arch Pharmacol 1996;354:618-26
   Google Scholar
• Battaglia G, Rustioni A. Coexistence of glutamate and substance P in dorsal root ganglion neurons of the rat and monkey. J Comp Neurol 1988;277:302-12
   PubMed Web of Science ®Google Scholar
• De Biasi S, Rustioni A. Glutamate and substance P coexist in primary afferent terminals in the superficial laminae of spinal cord. Proc Natl Acad Sci USA 1988;85:7820-4
   PubMed Web of Science ®Google Scholar
• Hokfelt T, Millhorn D, Seroogy K, et al. Coexistence of peptides with classical neurotransmitters. Experientia 1987;43:768-80
   PubMedGoogle Scholar
• Sergeyev V, Hokfelt T, Hurd Y. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport 1999;10:3967-70
   PubMed Web of Science ®Google Scholar
• Hahn MK, Bannon MJ. Tachykinin NK1 receptor antagonists enhance stress-induced c-fos in rat locus coeruleus. Eur J Pharmacol 1998;348:155-60
   PubMedGoogle Scholar
• Vaeroy H, Helle R, Forre O, et al. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988;32:21-6
   PubMed Web of Science ®Google Scholar
• Bradley LA, Sotolongo A, Alberts KR, et al. Abnormal regional cerebral blood flow in the caudate nucleus among fibromyalgia patients and non-patients is associated with insidious symptom onset. J Musculoskelet Pain 1999;7:285-92
   Web of Science ®Google Scholar
• Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-601
   PubMed Web of Science ®Google Scholar
• Liu Z, Welin M, Bragee B, Nyberg F. A high-recovery extraction procedure for quantitative analysis of substance P and opioid peptides in human cerebrospinal fluid. Peptides 2000;21:853-60
   PubMedGoogle Scholar
• Welin M, Bragee B, Nyberg F, Kristiansson M. Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in CSF from fibromyalgia patients. J Musculoskel Pain 1995;3(suppl 1):4
   Google Scholar
• Rimon R, Le Greves P, Nyberg F, et al. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol Psychiatry 1984;19:509-16
   PubMed Web of Science ®Google Scholar
• Heikkila L, Rimon R, Terenius L. Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res 1990;34:229-36
   PubMedGoogle Scholar
• Bondy B, Baghai TC, Minov C, et al. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry 2003;53:538-42
   PubMed Web of Science ®Google Scholar
• Geracioti TD Jr, Carpenter LL, Owens MJ, et al. Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 2006;163:637-43
   PubMed Web of Science ®Google Scholar
• Oblin A, Zivkovic B, Bartholini G. Involvement of the D-2 dopamine receptor in the neuroleptic-induced decrease in nigral substance P. Eur J Pharmacol 1984;105:175-7
   Google Scholar
• Brodin K, Ogren SO, Brodin E. Clomipramine and clonazepam increase cholecystokinin levels in rat ventral tegmental area and limbic regions. Eur J Pharmacol 1994;263:175-80
   Google Scholar
• Hamon M, Gozlan H, Bourgoin S, et al. Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology 1987;26:531-9
   Google Scholar
• Brodin E, Ogren S, Theodorsson-Norheim E. Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P-and neurokinin A/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat. Neuropharmacology 1987;26:581-90
   Google Scholar
• Shirayama Y, Mitsushio H, Takashima M, et al. Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 1996;739:70-8
   PubMed Web of Science ®Google Scholar
• Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997;82:291-5
   PubMed Web of Science ®Google Scholar
• Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001;64:43-51
   PubMed Web of Science ®Google Scholar
• Khanzode SD, Dakhale GN, Khanzode SS, et al. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003;8:365-70
   PubMed Web of Science ®Google Scholar
• Sarandol A, Sarandol E, Eker SS, et al. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharm Clin 2007;22:67-73
   PubMed Web of Science ®Google Scholar
• Herken H, Gurel A, Selek S, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007;38:247-52
   PubMed Web of Science ®Google Scholar
• Galecki P, Szemraj J, Bienkiewicz M, et al. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009;24:277-86
   PubMed Web of Science ®Google Scholar
• Szuster-Ciesielska A, Slotwinska M, Stachura A, et al. Accelerated apoptosis of blood leukocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:686-94
   PubMed Web of Science ®Google Scholar
• Savas HA, Herken H, Yurekli M, et al. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology 2002;45:57-61
   PubMed Web of Science ®Google Scholar
• Kim YK, Paik JW, Lee SW, et al. Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1091-6
   PubMedGoogle Scholar
• Oliveira RM, Guimaraes FS, Deakin JF. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008;41:333-41
   PubMed Web of Science ®Google Scholar
• Yanik M, Erel O, Kati M. The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatr 2004;16:200-3
   PubMed Web of Science ®Google Scholar
• Hein G, Franke S. Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology (Oxford) 2002;41:1163-7
   PubMed Web of Science ®Google Scholar
• Cordero MD, Moreno-Fernandez AM, Demiguel M, et al. Coenzyme Q10 distribution in blood is altered in patients with Fibromyalgia. Clin Biochem 2009;42:732-5
   PubMed Web of Science ®Google Scholar
• Wu J, Fang L, Lin Q, Willis WD. Nitric oxide synthase in spinal cord central sensitization following intradermal injection of capsaicin. Pain 2001;94:47-58
   PubMed Web of Science ®Google Scholar
• Larson AA, Giovengo SL, Russell IJ, Michalek JE. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000;87:201-11
   PubMed Web of Science ®Google Scholar
• Omoigui S. The biochemical origin of pain - Proposing a new law of pain: The origin of all pain is inflammation and the inflammatory response. Part 1 of 3 - A unifying law of pain. Med Hypotheses 2007;69:70-82
   Google Scholar
• Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31
   PubMed Web of Science ®Google Scholar
• Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:445-50
   PubMed Web of Science ®Google Scholar
• Younger WYY, Chen TJ, Hong CJ, et al. Association study of the interleukin-1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology 2003;28:1182-5
   Google Scholar
• Jun TY, Pae CU, Hoon H, et al. Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet 2003;13:179-81
   PubMed Web of Science ®Google Scholar
• Guo W, Wang H, Watanabe M, et al. Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci 2007;27:6006-18
   PubMed Web of Science ®Google Scholar
• Summer GJ, Romero-Sandoval EA, Bogen O, et al. Proinflammatory cytokines mediating burn-injury pain. Pain 2008;135:98-107
   Google Scholar
• Uceyler N, Eberle T, Rolke R, et al. Differential expression patterns of cytokines in complex regional pain syndrome. Pain 2007;132:195-205
   PubMed Web of Science ®Google Scholar
• Covey WC, Ignatowski TA, Knight PR, Spengler RN. Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res 2000;859:113-22
   PubMed Web of Science ®Google Scholar
• Reynolds JL, Ignatowski TA, Sud R, Spengler RN. Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant. J Pharmacol Exp Ther 2004;310:1216-25
   PubMedGoogle Scholar
• Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998;349:317-24
   PubMed Web of Science ®Google Scholar
• Mossner R, Heils A, Stober G, et al. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int 1998;33:251-4
   PubMed Web of Science ®Google Scholar
• Mossner R, Daniel S, Schmitt A, et al. Modulation of serotonin transporter function by interleukin-4. Life Sci 2001;68:873-80
   PubMed Web of Science ®Google Scholar
• Deak T, Bordner KA, McElderry NK, et al. Stress-induced increases in hypothalamic IL-1: a systematic analysis of multiple stressor paradigms. Brain Res Bull 2005;64:541-56
   PubMed Web of Science ®Google Scholar
• Merali Z, Du L, Hrdina P, et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 2004;24:1478-85
   PubMed Web of Science ®Google Scholar
• McBeth J, Silman AJ, Gupta A, et al. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain - Findings of a population-based prospective cohort study. Arthritis Rheum 2007;56:360-71
   PubMed Web of Science ®Google Scholar
• Kasckow JW, Baker D, Geracioti TD. Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 2001;22:845-51
   PubMed Web of Science ®Google Scholar
• Schafer M, Mousa SA, Zhang Q, et al. Expression of corticotropin-releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia. Proc Natl Acad Sci USA 1996;93:6096-100
   PubMed Web of Science ®Google Scholar
• Vit JP, Clauw DJ, Moallem T, et al. Analgesia and hyperalgesia from CRF receptor modulation in the central nervous system of Fischer and Lewis rats. Pain 2006;121:241-60
   PubMed Web of Science ®Google Scholar
• Mousa SA, Bopaiah CP, Richter JF, et al. Inhibition of inflammatory pain by CRF at peripheral, spinal and supraspinal sites: involvement of areas coexpressing CRF receptors and opioid peptides. Neuropsychopharmacology 2007;32:2530-42
   Google Scholar
• Coric V, Feldman HH, Oren DA, et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 2010;27:417-25
   PubMed Web of Science ®Google Scholar
• Ehnvall A, Mitchell PB, Hadzi-Pavlovic D, et al. Pain during depression and relationship to rejection sensitivity. Acta Psychiat Scand 2009;119:375-82
   Google Scholar
• Campbell S, Marriott M, Nahmias C, MacQueen GM. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004;161:598-607
   PubMed Web of Science ®Google Scholar
• Ballmaier M, Toga AW, Blanton RE, et al. Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: an MRI-based parcellation of the prefrontal cortex. Am J Psychiatry 2004;161:99-108
   PubMed Web of Science ®Google Scholar
• Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 2005;9:463-84
   PubMed Web of Science ®Google Scholar
• Giesecke T, Gracely RH, Williams DA, et al. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 2005;52:1577-84
   PubMed Web of Science ®Google Scholar
• Bar KJ, Wagner G, Koschke M, et al. Increased prefrontal activation during pain perception in major depression. Biol Psychiatry 2007;62:1281-7
   PubMedGoogle Scholar
• Magni G, Moreschi C, Rigatti-Luchini S, Merskey H. Prospective study on the relationship between depressive symptoms and chronic musculoskeletal pain. Pain 1994;56:289-97
   PubMed Web of Science ®Google Scholar
• Arnold LM, Hudson JI, Keck PE, et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006;67:1219-25
   PubMed Web of Science ®Google Scholar
• Kato K, Sullivan PF, Evengard B, Pedersen NL. Chronic widespread pain and its comorbidities: a population-based study. Arch Intern Med 2006;166:1649-54
   PubMedGoogle Scholar
• Kendler KS, Gatz M, Gardner CO, Pedersen NL. A Swedish national twin study of lifetime major depression. Am J Psychiatry 2006;163:109-14
   PubMed Web of Science ®Google Scholar
• Buskila D, Sarzi-Puttini P. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther 2006;8:218
   PubMed Web of Science ®Google Scholar
• Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-9
   PubMed Web of Science ®Google Scholar
• Waitekus AB, Kirkpatrick P. Duloxetine hydrochloride. Nat Rev Drug Discov 2004;3:907-8
   Google Scholar
• Boomershine CS, Crofford LJ. A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol 2009;5:191-9
   Web of Science ®Google Scholar
• Pae CU, Marks DM, Shah M, et al. Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol 2009;32:355-63
   PubMed Web of Science ®Google Scholar
• Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477-501
   PubMed Web of Science ®Google Scholar
• Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56
   PubMed Web of Science ®Google Scholar
• Guiard BP, El Mansari M, Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets 2009;10:1069-84
   PubMed Web of Science ®Google Scholar
• Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig 2008;5:142-7
   PubMed Web of Science ®Google Scholar
• Hache G, Coudore F, Gardier AM, Guiard BP. Monoaminergic antidepressants in the relief of pain: potential therapeutic utility of triple reuptake inhibitors (TRIs). Pharmaceuticals 2011;4:285-342
   Google Scholar
• Basile AS, Janowsky A, Golembiowska K, et al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther 2007;321:1208-25
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, et al. The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol Psychiatry 2005;57:640-6
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi SJ. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs 2009;14:439-53
   PubMed Web of Science ®Google Scholar
• Chancellor D. The depression market. Nat Rev Drug Discov 2011;10(11):809-10
   Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-52
   PubMed Web of Science ®Google Scholar
• Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370
   PubMed Web of Science ®Google Scholar
• Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009;6:53-77
   PubMed Web of Science ®Google Scholar
• de Bodinat C, Guardiola-Lemaitre B, Mocaer E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010;9:628-42
   PubMed Web of Science ®Google Scholar
• Korte SM. Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci Biobehav Rev 2001;25:117-42
   PubMed Web of Science ®Google Scholar
• Binneman B, Feltner D, Kolluri S, et al. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008;165(5):617-20
   PubMed Web of Science ®Google Scholar
• Kunzel HE, Zobel AW, Nickel T, et al. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 2003;37:525-33
   PubMed Web of Science ®Google Scholar
• Skofitsch G, Zamir N, Helke CJ, et al. Corticotropin releasing factor-like immunoreactivity in sensory ganglia and capsaicin sensitive neurons of the rat central nervous system: colocalization with other neuropeptides. Peptides 1985;6:307-18
   Google Scholar
• Korosi A, Kozicz T, Richter J, et al. Corticotropin-releasing factor, urocortin 1, and their receptors in the mouse spinal cord. J Comp Neurol 2007;502:973-89
   Google Scholar
• Ji G, Neugebauer V. Pro- and anti-nociceptive effects of corticotropin-releasing factor (CRF) in central amygdala neurons are mediated through different receptors. J Neurophysiol 2008;99:1201-12
   PubMed Web of Science ®Google Scholar
• Hummel M, Cummons T, Lu PM, et al. Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors. Neuropharmacology 2010;59:160-6
   Google Scholar
• Sluka KA, Winter OC, Wemmie JA. Acid-sensing ion channels: a new target for pain and CNS diseases. Curr Opin Drug Discov Devel 2009;12:693-704
   PubMedGoogle Scholar
• Wemmie JA, Taugher RJ, Kreple CJ. Acid-sensing ion channels in pain and disease. Nat Rev Neurosci 2013;14:461-71
   PubMed Web of Science ®Google Scholar
• Kang S, Jang JH, Price MP, et al. Simultaneous disruption of mouse ASIC1a, ASIC2 and ASIC3 genes enhances cutaneous mechanosensitivity. PLoS One 2012;7:e35225
   Google Scholar
• Chen CC, Zimmer A, Sun WH, et al. A role for ASIC3 in the modulation of high-intensity pain stimuli. Proc Natl Acad Sci USA 2002;99:8992-7
   PubMed Web of Science ®Google Scholar
• Wemmie JA, Price MP, Welsh MJ. Acid-sensing ion channels: advances, questions and therapeutic opportunities. Trends Neurosci 2006;29:578-86
   PubMed Web of Science ®Google Scholar
• Deval E, Gasull X, Noel J, et al. Acid-sensing ion channels (ASICs): pharmacology and implication in pain. Pharmacol Ther 2010;128:549-58
   PubMed Web of Science ®Google Scholar
• Coryell MW, Wunsch AM, Haenfler JM, et al. Acid-sensing ion channel-1a in the amygdala, a novel therapeutic target in depression-related behavior. J Neurosci 2009;29:5381-8
   Google Scholar
• Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010;71:616-26
   PubMed Web of Science ®Google Scholar
• San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008;23:396-402
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pandi-Perumal SR, Spence DW, et al. Potential use of melatonergic drugs in analgesia: mechanisms of action. Brain Res Bull 2010;81:362-71
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Srinivasan V, Spence DW, et al. Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther 2009;26:613-26
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-4
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-64
   PubMed Web of Science ®Google Scholar
• Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage 2000;19:S21-5
   PubMedGoogle Scholar
• Rao SG. The neuropharmacology of centrally-acting analgesic medications in fibromyalgia. Rheum Dis Clin North Am 2002;28:235-59
   PubMed Web of Science ®Google Scholar
• Wong WS, Chen PP, Yap J, et al. Chronic pain and psychiatric morbidity: a comparison between patients attending specialist orthopedics clinic and multidisciplinary pain clinic. Pain Med 2011;12:246-59
   Google Scholar
• Vaeroy H, Merskey H. The prevalence of current major depression and dysthymia in a Norwegian general practice. Acta Psychiatr Scand 1997;95:324-8
   PubMed Web of Science ®Google Scholar
• Husain MM, Rush AJ, Trivedi MH, et al. Pain in depression: STAR*D study findings. J Psychosom Res 2007;63:113-22
   PubMed Web of Science ®Google Scholar
• Kroenke K, Shen J, Oxman TE, et al. Impact of pain on the outcomes of depression treatment: results from the RESPECT trial. Pain 2008;134:209-15
   PubMed Web of Science ®Google Scholar
• Agüera-Ortiz L, Failde I, Mico J, et al. Pain as a symptom of depression: prevalence and clinical correlates in patients attending psychiatric clinics. J Affect Disord 2011;130:106-12
   PubMed Web of Science ®Google Scholar
• Lee P, Zhang M, Hong JP, et al. Frequency of painful physical symptoms with major depressive disorder in asia: relationship with disease severity and quality of life. J Clin Psychiatry 2009;70:83-91
   PubMed Web of Science ®Google Scholar
• Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. New Engl J Med 1999;341:1329-35
   PubMed Web of Science ®Google Scholar
• Lobo A, Garcia-Campayo J, Campos R, et al. Somatisation in primary care in Spain: I. Estimates of prevalence and clinical characteristics. Working Group for the Study of the Psychiatric and Psychosomatic Morbidity in Zaragoza. Br J Psychiatry 1996;168:344-8
   PubMed Web of Science ®Google Scholar
• Benjamin S, Barnes D, Berger S, et al. The relationship of chronic pain, mental illness and organic disorders. Pain 1988;32:185-95
   PubMed Web of Science ®Google Scholar
• Fishbain DA, Goldberg M, Meagher BR, et al. Male and female chronic pain patients categorized by DSM-III psychiatric diagnostic criteria. Pain 1986;26:181-97
   PubMed Web of Science ®Google Scholar
• Ho PT, Li CF, Ng YK, et al. Prevalence of and factors associated with psychiatric morbidity in chronic pain patients. J Psychosom Res 2011;70:541-7
   PubMed Web of Science ®Google Scholar
• Wilson KG, Mikail SF, D'Eon JL, Minns JE. Alternative diagnostic criteria for major depressive disorder in patients with chronic pain. Pain 2001;91:227-34
   PubMed Web of Science ®Google Scholar
• Delaplaine R, Ifabumuyi OI, Merskey H, Zarfas J. Significance of pain in psychiatric hospital patients. Pain 1978;4:361-6
   Google Scholar
• Pelz M, Merskey H, Brant CC, Heseltine GF. A note on the occurrence of pain in psychiatric patients from a Canadian indian and Inuit population. Pain 1981;10:75-8
   Google Scholar
• von Knorring L, Perris C, Eisemann M, et al. Pain as a symptom in depressive disorders. I. Relationship to diagnostic subgroup and depressive symptomatology. Pain 1983;15:19-26
   Web of Science ®Google Scholar
• Blumer D, Heilbronn M. Second-year follow-up study on systematic treatment of chronic pain with antidepressants. Henry Ford Hosp Med J 1981;29:67-8
   Google Scholar
• Kramlinger KG, Swanson DW, Maruta T. Are patients with chronic pain depressed? Am J Psychiatry 1983;140:747-9
   PubMed Web of Science ®Google Scholar
• Haley WE, Turner JA, Romano JM. Depression in chronic pain patients: relation to pain, activity, and sex differences. Pain 1985;23:337-43
   PubMed Web of Science ®Google Scholar
• Turner JA, Romano JM. Self-report screening measures for depression in chronic pain patients. J Clin Psychol 1984;40:909-13
   PubMed Web of Science ®Google Scholar
• Katon W, Egan K, Miller D. Chronic pain: lifetime psychiatric diagnoses and family history. Am J Psychiatry 1985;142:1156-60
   PubMed Web of Science ®Google Scholar
• Reich J, Tupin JP, Abramowitz SI. Psychiatric diagnosis of chronic pain patients. Am J Psychiatry 1983;140:1495-8
   PubMed Web of Science ®Google Scholar
• Merskey H, Spear FG. The concept of pain. J Psychosom Res 1967;11:59-67
   Google Scholar
• Singh G. The diagnosis of depression. Punjab Med J 1968;18:53-9
   Google Scholar
• Watts CA. The mild endogenous depression. Br Med J 1957;1:4-8
   Google Scholar
• Von Knorring L. The experience of pain in depressed patients. A clinical and experimental study. Neuropsychobiology 1975;1:155-65
   PubMedGoogle Scholar
• Devroye C, Filip M, Przegalinski E, et al. Serotonin receptors and drug addiction: focus on cocaine. Exp Brain Res 2013; Epub ahead of print
   Google Scholar